A meta-analysis that encompassed 17 studies suggested that 18F-FDG PET/CT radiomics could assist in predicting EGFR gene mutation status in NSCLC patients, achieving a pooled AUC of 0.82 (38). This evidence concerns the gene EGFR and non-small cell lung carcinoma.